TCGA-22-4599-01A-01R-1443-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- MTORC1_SIGNALING+0.500
- MYC_TARGETS_V1+0.460
- ALLOGRAFT_REJECTION+0.450
- G2M_CHECKPOINT+0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- OXIDATIVE_PHOSPHORYLATION+0.370
- INTERFERON_GAMMA_RESPONSE+0.360
- INFLAMMATORY_RESPONSE+0.330
- CHOLESTEROL_HOMEOSTASIS+0.300
Top 10 suppressed
- TGF_BETA_SIGNALING-0.450
- ESTROGEN_RESPONSE_EARLY-0.200
- UV_RESPONSE_DN-0.170
- APICAL_JUNCTION-0.160
- MITOTIC_SPINDLE-0.160
- ANDROGEN_RESPONSE-0.130
- COAGULATION-0.100
- MYOGENESIS-0.100
- TNFA_SIGNALING_VIA_NFKB-0.090
- ESTROGEN_RESPONSE_LATE-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-A9T5-01A-11R-A42T-07 | — | — | 0.849 |
| 2 | BSR_11_0148_A2_S91 | — | C | 0.829 |
| 3 | BSR_02_0048_A10_S104 | — | C | 0.829 |
| 4 | SRR35579824 | — | E | 0.825 |
| 5 | TCGA-C8-A1HF-01A-11R-A137-07 | — | C | 0.821 |
| 6 | MDT-AP-0368 | Med | Medulloblastoma | 0.813 |
| 7 | BS_996ZS2A4 | ATRT | — | 0.809 |
| 8 | TCGA-66-2791-01A-01R-0980-07 | — | cohortSQ2 | 0.806 |
| 9 | TCGA-A2-A0EQ-01A-11R-A034-07 | — | C | 0.804 |
| 10 | AUR-AF98-TTM1-A-1-1-R-A742-41 | — | E | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |